Key result
Saphenous vein grafts develop significant disease in approximately 50% of patients within the first decade, prompting percutaneous interventions whose optimal stent type remains unclear.
This review summarizes the current standard of care and ongoing controversies, such as the use of drug-eluting stents, in percutaneous interventions for saphenous vein graft disease.
Answers are grounded in this paper and cite their sources.
Optimal stent choice in SVG PCI remains uncertain; leaves open dedicated RCTs on DES vs alternatives.
While saphenous vein grafts continue to serve as the most common conduit in coronary artery bypass surgery, within the first decade approximately 50% will have developed significant disease. Percutaneous coronary intervention is often undertaken in patients with saphenous vein graft disease as an alternative to reoperation, but is associated with an increased risk of distal embolization, no-reflow, periprocedural myocardial infarction, and late restenosis. Evidence-based clinical trials have established the routine use of stents and distal protection devices as the standard of care for vein graft intervention. Nevertheless, questions persist as to the safety and efficacy of drug-eluting stents in vein grafts given that randomized trial data is minimal and contradictory. This review will examine the evolutionary advances and current status of interventional techniques in treating this problematic disease.
No takes yet. Share an insight, caveat, or question.
Rodriguez et al. (2010) conducted a review in Saphenous vein graft disease. Percutaneous coronary intervention was evaluated. Saphenous vein grafts develop significant disease in approximately 50% of patients within the first decade, prompting percutaneous interventions whose optimal stent type remains unclear.
Synapse has enriched 10 related papers. Consider them for comparative context: